Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates.

Lower healthy tissue uptake (toxicity) with loading dose When the total antibody dose increased from 0.3 mg kg −1 to 2.6 mg kg −1 , muscle uptake of the antibody–dye conjugate (%ID kg −1 ) showed a decreasing trend (Fig. 2a ), suggesting that co-administration of unlabeled antibody saturates the estimated glomerular filtration rate (EGFR)-binding sites in the muscle and thus reduces the target-mediated uptake (relevant for ADC toxicity) in healthy tissue.

also in 47,180 other papers